Live Breaking News & Updates on Patent Term

Stay updated with breaking news from Patent term. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Can Biologics Manufacturers Face Antitrust Risk For Pointing Out That Biosimilars Are Different? - Anti-trust/Competition Law

Can Biologics Manufacturers Face Antitrust Risk For Pointing Out That Biosimilars Are Different? - Anti-trust/Competition Law
mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.

Tony Hagen , Joe Franklin , Estee Lauder , Profl Publns Inc , Sys Ltd , Duty Free Arms Inc , Cable Wireless , Health Sys Inc , Mfrs Inc , Testing Serv Inc , Price Competition , Sherman Act , Biologics Price Competition , Innovation Act , Drug Price Competition , Patent Term , Restoration Act , Public Law , Interchangeable Products , More Treatment Choices , Difference Between , Interchangeable Biosimilar , None That , Duty Free Arms , Health Sys , Testing Serv ,

U.S. Patents for Nicox's Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term Extension Paris Stock Exchange:COX

and
for future
value as we continue the development of our clinical assets NCX 470 in glaucoma and NCX 4251 in blepharitis.”
Latanoprostene bunod, the pharmaceutical active ingredient in VYZULTA, was invented and patented by Nicox, and is the first product from the company’s proprietary nitric oxide-donating research platform to be approved for commercialization. Under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (also known as the “Hatch-Waxman Act”) certain patents for pharmaceutical products in the U.S. may be extended by up to 5 years once product approval from the FDA has been obtained. ....

New York , United States , Provence Alpes Côd Azur , Hong Kong , France General , United Kingdom , City Of , South Korea , Victor Floc H , Gavin Spencer , Yi Chen , Nicox Latanoprostene Bunod , Damien Choplain , Pharma Bio , Mary Ann Chang , Pooya Hemami , Sophia Antipolis , Sophie Baumont , Michele Garufi , Louise Chen , Kepler Cheuvreux , States Europe , Lifesci Advisors , Garnier Co , Drug Administration , Trademark Office ,

Review Of The 4th Amendment Of China's Patent Law - Intellectual Property

To print this article, all you need is to be registered or login on Mondaq.com.
Twelve years from the third amendment of China s patent law,
the fourth amendment was approved by the Standing Committee of the
National People s Congress on October 17, 2020. The new
amendment will take effect on June 1, 2021. This article provides a
detailed review of the changes from the current patent law.
Enhanced Protection of Patent Rights
The first aspect of changes relates to enhanced protection of
patent rights. Specifically, it includes punitive damages,
increased statutory damage, reversed burden of proof, increased
fine for passing‐off, and extended time limit for initiating ....

National People Congress On , Standing Committee , Property Administration , Products Administration , China National , National People , Punitive Damages , Increased Statutory , Reversed Burden , Increased Fine , Extended Time , Patent Term , Intellectual Property Administration , Patent Linkage , State Council , Patent Information Registration , Napproved Drugs , Drug Products , National Medical , Early Resolution Mechanism , Drug Patent Disputes , Trial Version , Drug Experimental Data , Waxman Act , New Grace Period , Patent Right Evaluation ,